Metformin and Rapamycin, two popular longevity drugs, have been shown to support immune health in elderly and high-risk subjects as well as decrease mortality in persons infected with COVID-19.

We discuss the science and rationale for prophylactic blood sugar health support in non-diabetics for longevity and immune health. 

Support your fasting lifestyle with Berberine HCl & Alpha Lipoic Acid by by MYOXCIENCE Nutrition: https://bit.ly/berberine-biotin-ala-stack

Use code Podcast to save

Related Podcast: Latest Breakthroughs In the Biology of Aging with Matt Kaeberlein, PhD

 

Time Stamps:

0:00 intro
0:38 mTOR inhibitors
1:15 Low Side effect profile
2:19 Metformin and influenza
2:50 Metabolic and immune health are one in the same
3:15 Aging and Immune Competence
3:52 Microdosing mTOR inhibitors
4:31 Dog Aging Project
5:07 Aging and Immunity
6:10 T Cells are Essential
6:55 Metformin was initially helpful for Influenza
8:11 Why chronic inflammation is bad
9:39 Pulsing mTOR inhibitors
13:38 Electrolytes and Creatine
14:19 Drugs are not always bad
15:28 Poor blood sugar control is a problem
18:20 Metformin and B Vitamins
19:15 Metformin and C*19

 

Articles Mentioned:

Bischof, E., C Siow, R., Zhavoronkov, A., & Kaeberlein, M. (2021). The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. The Lancet Healthy Longevity, 2(2), e105–e111. http://doi.org/10.1016/S2666-7568(20)30068-4

 

Bramante, C. T., Buse, J., Tamaritz, L., Palacio, A., Cohen, K., Vojta, D., et al. (2021). Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. Journal of Medical Virology, 93(7), 4273–4279.

Kruglikov, I. L., Shah, M., Elife, P. S.,. (2020). Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral–bacterial interactions. Elifesciences.org.

metabolism, A. S. D.,. (2020). Metformin and COVID-19: from cellular mechanisms to reduced mortality. Nutrition, Metabolism and Cardiovascular Diseases. http://doi.org/10.1016/j.diabet.2020.07.006